Field trials of methisazone as a prophylactic agent against smallpox.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000906:Antibodies / Q000032:analysis; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003140:Communicable Disease Control; D003168:Complement Fixation Tests; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006386:Hemagglutination Tests; D006801:Humans; D007223:Infant; D008297:Male; D009500:Neutralization Tests; D010154:Pakistan; D010865:Pilot Projects; D010919:Placebos; D012494:Sampling Studies; D012737:Sex Factors; D012899:Smallpox / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D013223:Statistics as Topic; D013882:Thiosemicarbazones / Q000009:adverse effects / Q000627:therapeutic use*; D014611:Vaccination; D014839:Vomiting / Q000139:chemically induced
D000906:Antibodies; D000998:Antiviral Agents; D010919:Placebos; D013882:Thiosemicarbazones